Annexon, Inc.
ANNXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Annexon, Inc. (ANNX) is listed under Biotechnology. The $950.3M market capitalization puts ANNX squarely in small-cap range for its industry. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Market Cap
$950.3M
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-6.28
EPS (TTM)
$-1.20
EPS (Fwd)
$-0.92
ROE
-87.6%
ROA
-45.3%
Cash
$225.0M
Total Debt
$25.4M
Free CF
-$107.3M
52W Change
150.0%
Annual Financials
Cash vs Debt
With $225.0M in cash and $25.4M in debt, ANNX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$107.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -87.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, ANNX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Annexon, Inc.'s trajectory.